Manufacturing issues have caused an interruption in the manufacturing and release of medicinal product Holoxan (ifosfamide) 1 g powder for solution for injection - 1 vial MA n. 023779061, resulting in a shortage (quota distribution) expected to continue until Q1 2027.

Baxter is the primary supplier of ifosfamide across the EU. Baxter S.p.A. is working with the manufacturing partner to restore normal supply as quickly as possible. The shortage is not due to any safety, efficacy or quality concern with currently available supplies of ifosfamide.

During this period, healthcare professionals should:

• ensure that sufficient supplies of ifosfamide are available to complete a treatment course, before starting any new patients on treatment.
• where necessary, ensure that patients who are already taking this medicine or for whom there are no suitable alternatives are prioritised for use of the limited supply.
• if necessary, consider prescribing an appropriate alternative treatment regime according to European treatment guidelines or local treatment protocols.
• advise concerned patients and caregivers to seek medical advice from their healthcare provider.